A detailed history of Bank Of Montreal transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Bank Of Montreal holds 10,031 shares of BGNE stock, worth $2.25 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,031
Previous 10,016 0.15%
Holding current value
$2.25 Million
Previous $1.57 Million 8.62%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$129.52 - $174.32 $1,942 - $2,614
15 Added 0.15%
10,031 $1.43 Million
Q1 2024

May 13, 2024

BUY
$141.8 - $181.47 $260,628 - $333,541
1,838 Added 22.47%
10,016 $1.57 Million
Q4 2023

Feb 08, 2024

SELL
$158.67 - $201.58 $103,928 - $132,034
-655 Reduced 7.42%
8,178 $1.47 Million
Q3 2023

Nov 01, 2023

SELL
$179.87 - $225.13 $645,193 - $807,541
-3,587 Reduced 28.88%
8,833 $1.59 Million
Q2 2023

Aug 02, 2023

SELL
$178.3 - $266.78 $110,546 - $165,403
-620 Reduced 4.75%
12,420 $2.21 Million
Q1 2023

Jun 13, 2024

BUY
$215.53 - $274.5 $689,049 - $877,576
3,197 Added 31.92%
13,213 $2.85 Million
Q4 2022

Feb 01, 2023

SELL
$125.51 - $229.3 $5.45 Million - $9.96 Million
-43,435 Reduced 76.91%
13,040 $2.87 Million
Q3 2022

Nov 10, 2022

SELL
$131.8 - $202.24 $3.11 Million - $4.77 Million
-23,587 Reduced 29.46%
56,475 $7.98 Million
Q2 2022

Aug 11, 2022

BUY
$121.11 - $216.05 $7.93 Million - $14.1 Million
65,491 Added 449.46%
80,062 $13.7 Million
Q1 2022

May 12, 2022

BUY
$146.52 - $269.56 $351,061 - $645,865
2,396 Added 19.68%
14,571 $3 Million
Q4 2021

Feb 11, 2022

SELL
$248.56 - $389.34 $2.59 Million - $4.05 Million
-10,406 Reduced 46.08%
12,175 $3.37 Million
Q3 2021

Nov 12, 2021

BUY
$249.6 - $403.14 $653,203 - $1.06 Million
2,617 Added 13.11%
22,581 $8.23 Million
Q2 2021

Aug 12, 2021

BUY
$292.75 - $367.01 $5.84 Million - $7.33 Million
19,964 New
19,964 $7.25 Million

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $23.3B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Bank Of Montreal Portfolio

Follow Bank Of Montreal and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of Montreal with notifications on news.